Cite
HARVARD Citation
Bril, V. et al. (2023). Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study. Lancet neurology. 22 (5), pp. 383-394. [Online].